Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Protheroe

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
The New England Journal of Medicine|June 6, 2017
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerKarim Fizazi, NamPhuong Tran, Luis Fein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2010
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancerCharles Comins, James Spicer, Andrew Protheroe, et al.
The Lancet. Oncology|January 13, 2018
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trialKim N Chi, Andrew Protheroe, Alfredo Rodríguez-Antolín, et al.
European Urology|October 4, 2018
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)John D Kelly, Wei Shen Tan, Nuria Porta, et al.
Prostate Cancer and Prostatic Diseases|October 26, 2023
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancerRobert Hugh Jones, Karim Fizazi, Nicholas D James, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillanceChristian Kollmannsberger, Torgrim Tandstad, Philippe L Bedard, et al.
European Urology Oncology|February 22, 2021
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS TrialBernadett Szabados, Alejo Rodriguez-Vida, Ignacio Durán, et al.
JAMA Oncology|June 3, 2016
Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal CancerThomas Powles, Naveed Sarwar, Andrew Stockdale, et al.
Journal for Immunotherapy of Cancer|June 28, 2020
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trialFederica Cappuccini, Richard Bryant, Emily Pollock, et al.
The Lancet. Oncology|March 29, 2012
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trialNicholas D James, Matthew R Sydes, Malcolm D Mason, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
The New England Journal of Medicine|June 6, 2017
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerKarim Fizazi, NamPhuong Tran, Luis Fein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2010
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancerCharles Comins, James Spicer, Andrew Protheroe, et al.
The Lancet. Oncology|January 13, 2018
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trialKim N Chi, Andrew Protheroe, Alfredo Rodríguez-Antolín, et al.
European Urology|October 4, 2018
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)John D Kelly, Wei Shen Tan, Nuria Porta, et al.
Prostate Cancer and Prostatic Diseases|October 26, 2023
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancerRobert Hugh Jones, Karim Fizazi, Nicholas D James, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillanceChristian Kollmannsberger, Torgrim Tandstad, Philippe L Bedard, et al.
European Urology Oncology|February 22, 2021
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS TrialBernadett Szabados, Alejo Rodriguez-Vida, Ignacio Durán, et al.
JAMA Oncology|June 3, 2016
Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal CancerThomas Powles, Naveed Sarwar, Andrew Stockdale, et al.
Journal for Immunotherapy of Cancer|June 28, 2020
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trialFederica Cappuccini, Richard Bryant, Emily Pollock, et al.
The Lancet. Oncology|March 29, 2012
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trialNicholas D James, Matthew R Sydes, Malcolm D Mason, et al.
Pageof 9